跳至主要内容
临床试验/NCT00192803
NCT00192803Unknown4 期

ACE/ACE2 Ratio in Diabetic Patients Treated With Antihypertensive Drugs

Rambam Health Care Campus1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2005年9月19日最近更新:
适应症
相关药物

试验速览

阶段
4 期
入组人数
20
试验地点
1
主要终点
ACE and ACE2 activities in monocytes

研究概览

简要总结

This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) antagonist, Candesartan.

This study will provide a closer insight to the possible involvement of the renin-angiotensin system (RAS)-related enzymatic components in development or attenuation of vascular pathogenesis.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Ect
盲法
None

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent
  • Non-smokers
  • Type II DM diagnosed patients
  • Blood pressure < 135/90
  • Serum HbA1C > 7%
  • Serum creatinine < 1mg%
  • Urine microalbumin < 300 mg/day
  • Body mass index (BMI) < 35 kg/m2

排除标准

  • Insulin-dependent diabetic patients
  • Patient with persistent microalbuminuria
  • Patient with history of severe hypertension
  • Congestive heart failure
  • Patient receiving renin-angiotensin-aldosterone system (RAAS)-related anti-hypertensive medications.
  • Patient with major hepatic disease

结局指标

主要结局

ACE and ACE2 activities in monocytes

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验